Quick Answer
Amphastar Pharmaceuticals, Inc. reported Research And Development Expense of $85.84 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +16.1% in Research And Development Expense from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $7.79 million | Q3 2013: $9.04 million | Q1 2014: $6.21 million | Q2 2014: $5.99 million | Q3 2014: $8.59 million | Q1 2015: $6.57 million | Q2 2015: $10.73 million | Q3 2015: $11.12 million | Q1 2016: $8.61 million | Q2 2016: $10.59 million | Q3 2016: $9.72 million | Q1 2017: $11.25 million | Q2 2017: $10.73 million | Q3 2017: $10.08 million | Q1 2018: $14.03 million | Q2 2018: $15.46 million | Q3 2018: $11.34 million | Q1 2019: $14.61 million | Q2 2019: $16.00 million | Q3 2019: $18.61 million | Q1 2020: $15.30 million | Q2 2020: $16.15 million | Q3 2020: $17.64 million | Q1 2021: $14.77 million | Q2 2021: $18.12 million | Q3 2021: $10.76 million | Q1 2022: $16.22 million | Q2 2022: $22.80 million | Q3 2022: $18.51 million | Q1 2023: $19.82 million | Q2 2023: $16.84 million | Q3 2023: $16.66 million | Q1 2024: $17.04 million | Q2 2024: $17.65 million | Q3 2024: $21.08 million | Q1 2025: $20.10 million | Q2 2025: $20.08 million | Q3 2025: $22.35 million.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Research And Development Expense has grown by 175.5%.
- Historical annual values: Fiscal year 2025: $85.84 million | Fiscal year 2024: $73.91 million | Fiscal year 2023: $73.74 million | Fiscal year 2022: $74.77 million | Fiscal year 2021: $60.93 million | Fiscal year 2020: $67.23 million | Fiscal year 2019: $68.85 million | Fiscal year 2018: $57.56 million | Fiscal year 2017: $43.50 million | Fiscal year 2016: $41.52 million | Fiscal year 2015: $37.27 million | Fiscal year 2014: $28.87 million | Fiscal year 2013: $33.02 million | Fiscal year 2012: $31.16 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: